uniQure NV (QURE) Upgraded to “Hold” by Zacks Investment Research
uniQure NV (NASDAQ:QURE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
Other research analysts also recently issued research reports about the company. Leerink Swann reaffirmed a “buy” rating on shares of uniQure NV in a report on Sunday, June 12th. HC Wainwright began coverage on uniQure NV in a report on Thursday, August 4th. They set a “buy” rating and a $21.00 target price on the stock. Cowen and Company reaffirmed a “buy” rating on shares of uniQure NV in a report on Thursday, June 2nd. Jefferies Group set a $28.00 target price on uniQure NV and gave the stock a “buy” rating in a report on Thursday, July 28th. Finally, Chardan Capital set a $35.00 target price on uniQure NV and gave the stock a “buy” rating in a report on Thursday, July 28th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $28.10.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/uniqure-nv-qure-upgraded-to-hold-by-zacks-investment-research.html
uniQure NV (NASDAQ:QURE) traded down 2.15% during mid-day trading on Wednesday, hitting $7.75. The company had a trading volume of 302,311 shares. The stock’s 50 day moving average price is $8.23 and its 200 day moving average price is $10.36. The firm’s market cap is $194.75 million. uniQure NV has a 52-week low of $6.68 and a 52-week high of $27.65.
uniQure NV (NASDAQ:QURE) last issued its quarterly earnings results on Thursday, August 25th. The company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.02. uniQure NV had a negative return on equity of 61.96% and a negative net margin of 537.62%. On average, equities research analysts predict that uniQure NV will post ($3.71) EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of QURE. JPMorgan Chase & Co. boosted its stake in uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock valued at $104,000 after buying an additional 5,760 shares in the last quarter. TFS Capital LLC boosted its stake in uniQure NV by 3.0% in the second quarter. TFS Capital LLC now owns 15,156 shares of the company’s stock valued at $112,000 after buying an additional 437 shares in the last quarter. Princeton Alpha Management LP acquired a new stake in uniQure NV during the second quarter valued at approximately $120,000. Fox Run Management L.L.C. acquired a new stake in uniQure NV during the second quarter valued at approximately $122,000. Finally, Acrospire Investment Management LLC boosted its stake in uniQure NV by 355.2% in the second quarter. Acrospire Investment Management LLC now owns 17,298 shares of the company’s stock valued at $127,000 after buying an additional 13,498 shares in the last quarter. Hedge funds and other institutional investors own 32.38% of the company’s stock.
About uniQure NV
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related companies with MarketBeat.com's FREE daily email newsletter.